Twist Bioscience (NASDAQ:TWST) Price Target Raised to $48.00 at Leerink Partners

Twist Bioscience (NASDAQ:TWST - Free Report) had its price objective increased by Leerink Partners from $45.00 to $48.00 in a research note issued to investors on Thursday morning, Benzinga reports. The firm currently has a market perform rating on the stock.

Several other equities research analysts have also weighed in on TWST. Robert W. Baird increased their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an "outperform" rating in a research note on Monday, August 5th. The Goldman Sachs Group increased their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, July 9th. Evercore ISI raised their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research note on Monday, August 5th. Finally, Barclays dropped their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $51.22.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST traded up $0.45 during trading on Thursday, reaching $45.52. 761,784 shares of the company's stock traded hands, compared to its average volume of 968,046. The stock has a market capitalization of $2.65 billion, a P/E ratio of -13.40 and a beta of 1.77. Twist Bioscience has a 12 month low of $14.42 and a 12 month high of $60.90. The company has a 50 day moving average of $43.91 and a 200-day moving average of $44.20.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The business had revenue of $81.50 million for the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. Twist Bioscience's revenue was up 27.7% compared to the same quarter last year. During the same quarter last year, the company earned ($1.01) EPS. Equities research analysts predict that Twist Bioscience will post -3.13 earnings per share for the current fiscal year.

Insider Activity at Twist Bioscience

In related news, SVP Paula Green sold 1,137 shares of the firm's stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $45,400.41. Following the transaction, the senior vice president now owns 88,837 shares in the company, valued at $3,547,261.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Paula Green sold 1,137 shares of the firm's stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $45,400.41. Following the completion of the sale, the senior vice president now directly owns 88,837 shares in the company, valued at approximately $3,547,261.41. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Adam Laponis sold 856 shares of the firm's stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total transaction of $35,789.36. Following the sale, the chief financial officer now owns 73,397 shares of the company's stock, valued at $3,068,728.57. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,246 shares of company stock worth $1,829,356 over the last quarter. 3.92% of the stock is currently owned by company insiders.

Institutional Trading of Twist Bioscience

A number of large investors have recently added to or reduced their stakes in the business. Baillie Gifford & Co. boosted its stake in Twist Bioscience by 12.1% in the 1st quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company's stock worth $42,116,000 after purchasing an additional 132,770 shares during the period. Point72 Asset Management L.P. boosted its stake in Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company's stock worth $33,168,000 after purchasing an additional 613,057 shares during the period. Fred Alger Management LLC boosted its stake in Twist Bioscience by 720.7% in the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company's stock worth $32,272,000 after purchasing an additional 575,080 shares during the period. Driehaus Capital Management LLC boosted its stake in shares of Twist Bioscience by 63.0% during the 2nd quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company's stock valued at $19,152,000 after buying an additional 150,260 shares during the period. Finally, Ensign Peak Advisors Inc boosted its stake in shares of Twist Bioscience by 74.6% during the 2nd quarter. Ensign Peak Advisors Inc now owns 331,373 shares of the company's stock valued at $16,330,000 after buying an additional 141,557 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.